iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
13 mai 2024 16h05 HE
|
iBio, Inc.
Strengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 ...
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
27 mars 2024 07h00 HE
|
iBio, Inc.
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover,...
iBio Announces $15.0 Million Private Placement
26 mars 2024 19h35 HE
|
iBio, Inc.
– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an...
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
26 févr. 2024 07h45 HE
|
iBio, Inc.
– Deal includes $1 million upfront and potential future milestone payments – – iBio’s proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – ...
iBio Announces Participation in 23rd Annual PepTalk Conference
16 janv. 2024 08h15 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that...
iBio Amends and Extends Maturity of Credit Agreement
26 déc. 2023 07h15 HE
|
iBio, Inc.
– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --...
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
05 déc. 2023 08h00 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of...
iBio Announces Reverse Stock Split
27 nov. 2023 17h20 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of...
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
01 nov. 2023 08h24 HE
|
iBio, Inc.
- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- iBio,...
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
10 oct. 2023 08h00 HE
|
iBio, Inc.
- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas...